The American Hospital Association's initial comment on the Health Resources and Services Administration’s (HRSA) request for information regarding a 340B Rebate Model Pilot Program.

The Trump administration agreed to drop a controversial pilot that would have allowed drugmakers to give post-sales rebates on some drugs instead of upfront discounts.

HHS is scrapping its proposed 340B rebate pilot after hospitals sued to stop it. Providers say the plan would have created cash flow problems and administrative burdens that threatened safety-net care ...

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...

The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

Only a week after calling it quits on a court-halted pilot program, the Trump administration is already revving the engine on how it could test out a rebate model for the 340B Drug Discount program | ...

The Tungsten+PLUS™ platform delivers comprehensive downstream services, including MFP claims reconciliation, dispute ...

When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...